Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures

Bone

Volumn 50, Issue 5, 2012, Pages 1196-1200

  Abrahamsen, Bo ^a,b   Einhorn, Thomas A ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atypical femur fractures; Bisphosphonates; Epidemiology; Osteoporosis; Pathophysiology

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; GLUCOCORTICOID; PLACEBO; PROTON PUMP INHIBITOR; RALOXIFENE; ZOLEDRONIC ACID;

ATYPICAL FEMUR FRACTURE; BIOMECHANICS; BONE DEFORMATION; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FRAGILITY FRACTURE; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; NONHUMAN; NOTE; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; VITAMIN D DEFICIENCY;

BIOMECHANICS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; RISK FACTORS;

EID: 84859435420     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.02.009     Document Type: Note

References (23)

1. Neviaser A., Lane J., Lenart B., et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
2. Odvina C., Zerwekh J., Rao D., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
3. Shane E., Burr D., Ebeling P., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research. J Bone Miner Res 2010, 25:2267-2294.
4. Morgan E., Barnes G., Einhorn T. Osteoporosis - third edition 2008, 3-25. R. Marcus, D. Feldman, D. Nelson, C. Rosen (Eds.).
5. Kwek E., Goh S., Koh J., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
6. Isaacs J., Shidiak L., Harris I., et al. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 2010, 468:3384-3392.
7. Pauwels F. Bedeutung des Bauprinzipien des Stütz und Bewegungsappates. Z Anat Entwicklungsgesch 1948, 129-166.
8. Koh J.S.B., Goh S.K., Png M.A. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 2011, 52:77-80.
9. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
10. Jamal S.A., Dion N., Ste-Marie L. Atypical femoral fractures and bone turnover. N Engl J Med 2011, 365:1261-1262.
11. Brennan O., Kennedy O.D., Lee T.C. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. J Orthop Res 2011, 29:419-424.
12. Wright J.G., Swiontkowski M., Heckman J.D. Levels of evidence. J Bone Joint Surg Br 2006, 88:1264.
13. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789.
14. Nieves J., Bilezikian J., Lane J., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporosis Int Mar 2010, 21(3):399-408.
15. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560.
16. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
17. Dell R., Greene D., Ott S., et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009 (abstract). JBMR 2010, S1:1201.
18. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
19. Black D., Kelly M., Genant H., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med May 13 2010, 362(19):1761-1771.
20. Kim S.Y., Schneeweiss S., Katz J.N. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011, 26:993-1001.
21. Feldstein A., Black D., Perrin N., Rosales A.G., Friess D., Boardman D., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. Jan 24 2012, (online). 10.1002/jbmr.1550.
22. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
23. Giusti A., Hamdy N.A.T., Dekkers O.M. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48:966-971.